All News
Filter News
Found 3,313 articles
-
Genmab Publishes 2023 Annual Report
2/14/2024
Genmab A/S announced the publication of its Annual Report for 2023.
-
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
2/13/2024
Cingulate Inc. announced that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin.
-
Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors
2/13/2024
Onconetix, Inc. announced the appointment of Ajit Singh, Ph.D. and Thomas Meier, Ph.D. to its Board of Directors.
-
Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board
2/13/2024
Molecular Assemblies, Inc. today announced the addition of two industry leaders to its Commercial-Technology Advisory Board (CTAB), which includes experts in the commercialization of nucleic acid technologies and innovative life science product solutions.
-
Dave Amerson and Tyler Binney Add Their Experience Commercializing Disruptive Technologies to Intrinsic Therapeutics' Board of Directors
2/13/2024
Intrinsic Therapeutics, Inc. announced the appointment of Dave Amerson and Tyler Binney to its Board of Directors.
-
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
2/12/2024
Connect Biopharma Holdings Limited announced the appointment of James Zuie-chin Huang, M.B.A., to its Board of Directors effective immediately.
-
Baxter Reports Fourth-Quarter and Full-Year 2023 Results
2/8/2024
Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
-
Arkuda Therapeutics Announces Option and Asset Purchase Agreement
2/7/2024
Arkuda Therapeutics today announced that it entered into an option and asset purchase agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, which grants Janssen an exclusive option to purchase Arkuda's portfolio of lysosomal function enhancers.
-
The monoclonal antibody Nipocalimab, which J&J acquired from Momenta Therapeutics, met its primary endpoints in mid-stage and late-stage trials in myasthenia gravis and Sjögren’s disease.
-
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
2/6/2024
Femasys Inc. today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024.
-
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
2/2/2024
Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2023, which reflect strong pipeline acceleration, continued portfolio diversification, and momentum in our business.
-
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
2/2/2024
Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA) of tisotumab vedotin, an antibody-drug conjugate (ADC), developed for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.
-
Align Technology Announces Fourth Quarter and Fiscal 2023 Financial Results
1/31/2024
Align Technology, Inc., a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, reported financial results for the fourth quarter and year ended December 31, 2023.
-
Abdera Therapeutics Expands Management Team and Board of Directors
1/30/2024
Abdera Therapeutics Inc. today announced the appointments of Philippe Bishop, M.D., as chief medical officer and Eric Dobmeier as a member of the company’s board of directors.
-
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
1/29/2024
Madrigal Pharmaceuticals, Inc. today announced three new members of its leadership team: Mark Barrett joins Madrigal as Chief Business Officer, Clint Wallace joins as Chief Human Resources Officer and Tina Ventura joins as Chief Investor Relations Officer.
-
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
1/26/2024
Vanda Pharmaceuticals Inc. announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating treatment after missed doses.
-
Johnson & Johnson exceeded fourth-quarter earnings estimates, reporting nearly $21.4 billion in revenue, as its pharma business faces a patent cliff with Stelara competition entering the market.
-
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
1/23/2024
Johnson & Johnson announced results for fourth-quarter and full year 2023. “Johnson & Johnson’s full year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said Joaquin Duato, Chairman and Chief Executive Officer.
-
Tim Czartoski Appointed as CEO of Genesis Innovation Group
1/22/2024
Genesis Innovation Group is excited to announce the appointment of Tim Czartoski as Chief Executive Officer effective April 1, 2024, and serving in an advisory role until that time.
-
People who worked in the industry around the time that BioSpace launched its Hotbeds Maps—including Marc Goldberg, a MassBio co-founder, and Biocom leader Joe Panetta—spoke with us about their experiences.